NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
NewAmsterdam Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...
NewAmsterdam Pharma Company (NAMS) Gets a Buy from Scotiabank
Scotiabank analyst George Farmer maintained a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report) today and set a price target ...
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) revealed topline data from its Phase 3 BROADWAY clinical trial evaluating ...
The Pharma Letter18h
NewAmsterdam leaps on positive trial results
Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research ...
BioPharma Dive1d
NewAmsterdam drug shows ‘unexpected’ signs of protecting the heart in latest study
The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned ...
bovnews1d
NewAmsterdam Pharma (NAMS) Shatters Expectations: Why Its Stock is Soaring Today
NewAmsterdam Pharma (Nasdaq: NAMS) took a commanding leap in the stock market, thanks to the announcement of positive topline data from its Phase 3 BROADWAY clinical trial. This trial evaluated ...
NewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Recommendation of “Buy” from Analysts
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) has earned an average recommendation of “Buy” from the six research firms ...
Hosted on MSN1d
NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug
NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...